Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMA NASDAQ:MAAQ NASDAQ:MNOV NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.83$5.74$3.94▼$18.00$62.11M0.7311,355 shs8,136 shsMAAQMana Capital Acquisition$1.99-5.7%$1.88$5.35▼$10.25$48.67MN/A33,075 shs52,322 shsMNOVMediciNova$1.43$1.35$1.17▼$1.96$70.39M0.6273,954 shs27,464 shsPMVPPMV Pharmaceuticals$1.22$1.25$1.02▼$1.88$65.07M1.33274,386 shs143,416 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio0.00%-0.93%+2.46%+17.30%-62.91%MAAQMana Capital Acquisition0.00%-1.00%-15.32%-2.45%-44.88%MNOVMediciNova0.00%+11.72%+8.33%-0.69%+12.60%PMVPPMV Pharmaceuticals0.00%+2.52%+2.52%-8.96%+10.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.83$5.74$3.94▼$18.00$62.11M0.7311,355 shs8,136 shsMAAQMana Capital Acquisition$1.99-5.7%$1.88$5.35▼$10.25$48.67MN/A33,075 shs52,322 shsMNOVMediciNova$1.43$1.35$1.17▼$1.96$70.39M0.6273,954 shs27,464 shsPMVPPMV Pharmaceuticals$1.22$1.25$1.02▼$1.88$65.07M1.33274,386 shs143,416 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio0.00%-0.93%+2.46%+17.30%-62.91%MAAQMana Capital Acquisition0.00%-1.00%-15.32%-2.45%-44.88%MNOVMediciNova0.00%+11.72%+8.33%-0.69%+12.60%PMVPPMV Pharmaceuticals0.00%+2.52%+2.52%-8.96%+10.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMAImageneBio 2.00Hold$26.50354.55% UpsideMAAQMana Capital Acquisition 0.00N/AN/AN/AMNOVMediciNova 2.67Moderate Buy$8.33482.75% UpsidePMVPPMV Pharmaceuticals 2.67Moderate Buy$5.00309.84% UpsideCurrent Analyst Ratings BreakdownLatest MAAQ, MNOV, IMA, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026IMAImageneBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026MNOVMediciNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PMVPPMV Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $5.005/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform5/4/2026MNOVMediciNova D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMAImageneBio$800K77.61N/AN/A$11.91 per share0.49MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMNOVMediciNova$410K171.67N/AN/A$0.85 per share1.68PMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/AMNOVMediciNova-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%8/13/2026 (Estimated)PMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%8/6/2026 (Estimated)Latest MAAQ, MNOV, IMA, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNOVMediciNova-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million5/12/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41-$0.34+$0.07-$0.34N/AN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMAImageneBioN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMAImageneBioN/A18.3918.39MAAQMana Capital AcquisitionN/AN/AN/AMNOVMediciNovaN/A9.099.09PMVPPMV PharmaceuticalsN/A11.1411.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMAImageneBio75.00%MAAQMana Capital Acquisition68.44%MNOVMediciNova9.90%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipIMAImageneBio2.22%MAAQMana Capital AcquisitionN/AMNOVMediciNova14.00%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMAImageneBio7010.65 million10.42 millionNot OptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMNOVMediciNova1049.22 million42.33 millionOptionablePMVPPMV Pharmaceuticals5053.33 million49.30 millionOptionableMAAQ, MNOV, IMA, and PMVP HeadlinesRecent News About These CompaniesPMV Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:PMVPJune 25, 2026 | benzinga.comPMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's WhyJune 24, 2026 | zacks.comPMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerJune 10, 2026 | zacks.comWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 3, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 2, 2026 | insidermonkey.comPMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84April 28, 2026 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | finanznachrichten.dePMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | globenewswire.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?April 20, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.84%March 9, 2026 | aaii.comAPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsMarch 6, 2026 | globenewswire.comNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsFebruary 27, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 8.04%February 27, 2026 | aaii.comAPMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial ComparisonNovember 23, 2025 | defenseworld.netDPMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)November 12, 2025 | msn.comPMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate HighlightsNovember 12, 2025 | markets.businessinsider.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?October 28, 2025 | finance.yahoo.comPMV Pharmaceuticals stock rises on positive cancer drug trial dataOctober 24, 2025 | in.investing.comPMV Pharmaceuticals announces updated rezatapopt monotherapy interim dataOctober 24, 2025 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a ...October 24, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 2026Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreBy Leo Miller | June 19, 2026NextEra’s Dominion Deal Could Put It at the Center of the AI Power RaceBy Nathan Reiff | June 30, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026Planet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026MAAQ, MNOV, IMA, and PMVP Company DescriptionsImageneBio NASDAQ:IMA$5.83 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.84 +0.00 (+0.09%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Mana Capital Acquisition NASDAQ:MAAQ$1.99 -0.12 (-5.69%) As of 07/2/2026Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.MediciNova NASDAQ:MNOV$1.43 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.70%) As of 07/2/2026 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.PMV Pharmaceuticals NASDAQ:PMVP$1.22 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.41%) As of 07/2/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
